The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

This publication has 87 references indexed in Scilit:

• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus
  Diabetologia, 2006
• Twelve-week Monotherapy with the DPP-4 Inhibitor Vildagliptin Improves Glycemic Control in Subjects with Type 2 Diabetes
  Hormone and Metabolic Research, 2006
• Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin
  Diabetes/Metabolism Research and Reviews, 2006
• Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
  Diabetes Care, 2004
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
  Circulation, 2004
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
  Journal of Biological Chemistry, 2003
• Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans.
  Journal of Clinical Investigation, 1998
• Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
  European Journal of Biochemistry, 1993
• Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
  Digestive Diseases and Sciences, 1993
• Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes Mellitus
  New England Journal of Medicine, 1988